Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
89 hedge funds and large institutions have $819M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 7 closing their positions.
486% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 7
162% more capital invested
Capital invested by funds: $313M → $819M (+$506M)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
62% more funds holding
Funds holding: 55 → 89 (+34)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$19.3M |
| 2 |
Janus Henderson Group
London,
|
+$16.4M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$14M |
| 4 |
O
OrbiMed
New York
|
+$13.9M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$19.4M |
| 2 |
Millennium Management
New York
|
-$6.29M |
| 3 |
JP Morgan Chase
New York
|
-$2.84M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.5M |
| 5 |
EP
Eversept Partners
New York
|
-$2.22M |
DCPH Hedge Fund Activity: Q2 2018 in Review
89 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2018, worth a combined $819M — up 162% from $313M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new DCPH positions and 7 closed out — a net gain of 34 holders — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Redmile Group, adding an estimated $19.3M. The largest seller was Viking Global Investors, cutting an estimated $19.4M.
- 89 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2018, up from 55 in Q1 2018.
- Funds reported $819M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2018, up 162% quarter-over-quarter.
- 41 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2018 and 7 closed out, a net change of +34 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q2 2018 was Redmile Group, an estimated $19.3M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2018 was Viking Global Investors, an estimated $19.4M sold.
Based on aggregated 13F filings for Q2 2018.